The Indian pharmaceutical industry has fast growing at the rate of 14 percent per year [Indian brand equality foundation, 2009] and its ranks is very high in the third world, in terms of technology, quality and range of medicines manufactured. A rapid expansion and sophistication of chemical and pharmaceutical industries has increased the amount and complexity of toxic waste effluents. The effective removal of substances included in pharmaceutical effluents is a challenging task due to the wide variety of Chemicals produced biological products ,medicinal chemicals , botanical products in drug manufacturing plants such as analgesic, antibiotics, antidepressants, antidiabetics, contracepes, growth regulators, drugs, painkillers, and tranuilizers (Robinson et al., 2007; Ghauch et al., 2009) which lead to wastewaters of variable compositions into natural systems and consequent degradation of the environment (Mehta, G at al.1995). The effluent generated from these industries is typically toxics, colored, organic and turbid with high suspended solids. This in turn has led to an increase in various kinds of diseases. For example many organic compounds that are recalcitrant in nature are produced while manufacturing pharmaceutical products, while most of them that are poorly degradable are released in effluent. And sometimes formation of N-nitrosamines, a possible carcinogen in stomach another issue of ecological concern is causing of algal blooms or eutrophication in water bodies (Chih-Hsiang Liao et al., 2003). The pharmaceutical effluents were treated by traditional techniques such as flocculation, coagulation, conventional biological treatment, filtration, reverse osmosis, precipitation ,incineration, and triple effect evaporator because of high TDS. In these approaches, the pollutants are transferred from a liquid phase to a solid phase (Takaoka et al., 2007), and also facing corrosion problems. A biological treatment is highly effective for the removal of most contaminants, however biodegradation processes are inherently slow and do not allow for high degrees of removal. The sludge formed during biological treatment has to be disposed either by land filling or burning, which increases considerably the running costs. In addition, sludge disposal may pose further environmental problems.( Noelia Barrabes et al., 2011) In this sense, catalytic process appears as the most promising technology. Current pharmaceutical industry were practicing triple effect evaporate for treatment of high dissolved solids, in these route high amount of sludge is generated and also high amount of steam required. Now a day the researchers are mainly focus on the eco-friendly and economically viable technologies are much desirable in these days.
Introduction The Indian Pharmaceutical Industry is in the front rank of India’s science based industries. It is a highly organized sector. The Industry is estimated to be of worth $ 4.5 billion, with growth of about 8 to 9% annually. It ranks very high in terms of technology, quality and range of manufactured medicines. From simple headache pills to heavy antibiotics and complex cardiac compounds, almost each and every type of medicine is now made indigenously. It meets around 70% of the country's
products, it is still very low due to the patents protection but in case of the expired patents, it is medium. A pharmaceutical company has lots of way to fight back against generic drugs such as obtaining patents on component chemicals, manufacturing methods, product extension/formula modifications or improving drug-delivery methods. Rivalry among existing firms is medium. Each pharmaceutical company has to fight in order to take an advantage of the first one who obtains patents. Moreover they are competing
this also comprises of the applicable taxes(Acne free, 2012). Indian OTC pharmaceuticals industry has grown at a strong rate from the period in between 2008-2012. In this there has been a major increase in the growth of vitamin and minerals division. It is a trend which is forecasted till 2017(OTC pharmaceutical India, 2013). There is a growing demand for anti- acne products in India and the market of Indian OTC pharmaceuticals industry has recorded its total revenue worth 1,834.2 million USD during
Eli Lilly and Company is an American global pharmaceutical company. Colonel Eli Lilly, a pharmaceutical chemist and veteran of the U.S. Civil War, founded Eli Lilly and Company on May 10th, 1876 in the state of Indiana, Indianapolis which is where the company's headquarters are currently located. Eli Lilly is the 10th largest pharmaceutical company in the world and is dedicated to creating medicines that help improve peoples' quality of life. Eli Lilly is also the world's largest manufacturer and
pinnacle of Indian pharmaceutical industry. Indomitable and indefatigable as he may be, he had held the helm for ages now, and it was time for his nephew Kamil to steer the ship forward. But as it turned out Yusuf Hamied was staring at Kamil Hamied’s official resignation, who decided to quit Cipla after 7 years to pursue his personal career objectives. Yusuf Hamied had been mentoring Kamil and his
the TRIPS Agreement. It was on April 15, 1994 that 117 nations ... ... middle of paper ... ...TRIPS patent laws in the important public health issue. RESEARCH METHODOLOGY This Dissertation, titled “Impact of TRIPS on Indian patent regime with reference to pharmaceutical sector” has been written and based on doctrinal method of research which involves the collection of data from secondary sources, like books written by authors and articles found in journals and websites. No empirical research
Conclusion: Indian formulation industry along with its counterpart pharmaceutical industry has been booming in recent years. Both, India and China have been major players in pharmaceutical sector in Asian as well as global market. Pharmaceutical sector is generating considerable revenue for the economy of both the countries. India is famous for the number of patents in pharmaceutical industry it has and its formulation industry while china is known for its economical price and ready availability
The Indian pharmaceutical industry enjoys certain advantages, which include low cost of innovation and capital expenditure, and strong domestic support in production, from raw material requirements to finished goods. The competitive structure of the pharmaceutical industry was being redefined due to the threat of new entrants, intense price competition, entry of large players, and new regulations and rules as well as a shift in focus. In addition, the partnerships between pharmaceutical and biotechnology
Following are the Objectives of this paper: • To explore Indian Glass Industry and its impact on Indian economy. • To study the challenges and threats to Indian Glass Industry. • To study the strengths and opportunities available to Indian Glass Industry. • To observe the sustainability of the growth of the industry. • To document the growth trend and future prospects of Indian glass industry. • Case study: Hindustan Glass and Industries Limited. The Term paper involved an Exploratory Research
Industry Definition According to the Encyclopedia of Global Industries, the Pharmaceutical Preparation Manufacturing industry can be defined as an industry that produces products or means for human and veterinary treatment. There two main segments of products in the pharmaceutical industry: pharmaceutical preparations and therapies. Pharmaceutical preparations include prescription or “ethical” drugs— products geared towards dental, medical, or veterinary professions, as well as “over-the-counter”
Introduction: The Indian Pharmaceutical Industry today is considered highly progressive industry among India's science-based industries with wide ranging capabilities in the field of drug manufacture and technology. India is considered to be global powerhouse of generic drugs. However, it is now witnessing regulatory challenges like delays in clinical trial approvals, uncertainties over the FDI policy, a uniform code for sales and marketing practices and compulsory licensing (M. Janodia, 2007). Key
delays and regulatory ambiguity have wrecked innovation as well as growth of the clinical trial industry. After the amendment in January 2013, ineffective regulatory oversight, need for protection for informed consent of vulnerable populations and compensation guidelines for patients for trial related deaths have materialized as chief concerns. Recently, Biocon has been compelled to move various Indian projects to the US and Europe. The situation only makes the process more cumbersome but also results
the stakes increment by UK based GlaxoSmithKline (GSK) in its Indian subsidiary (GSK Pharmaceutical Ltd) from 50.7% to 75%, despite the volatile regulatory environment relating to the pricing control of drugs and tension over patents issues (Ward 2014). The implementation of new price controls is also likely to result in smaller profit margin. However, the increased in stakes for GSK India signifies the confidence of GSK in the Indian market, the need for greater control and the intention to focus
Supply Chain Management at Nicholas Piramal India Case Study Supply chain management (SCM) is one of the leading cost saving and revenue enhancement strategies in use today. Pharmaceutical companies are increasingly using this technique to improve the entire functional process. SCM has also helped companies enhance their efficiency in managing resources and improving relationships. In the case of Nicholas Piramal, SCM has proved to be one of the most powerful engines of business transformation
INTRODUCTION Pharmaceutical industry in the United Kingdom The pharmaceutical industry in the United Kingdom directly employs around 72,000 people and in 2010 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion. The UK is home to GlaxoSmithKline and AstraZeneca, respectively the world's fifth- and